FDA Adds Meningioma Warning to Depo-Provera Label

What Changed in the Depo-Provera Label

The FDA-approved prescribing information for Depo-Provera now includes a warning concerning meningioma, a tumor arising from tissues surrounding the brain and spinal cord.

The label states that meningiomas have been reported following repeated administration of medroxyprogesterone acetate, primarily with long-term use.

It instructs healthcare professionals to monitor patients for signs and symptoms of meningioma and to discontinue Depo-Provera if a meningioma is diagnosed.

The update also adds meningioma information to the patient-counseling section of the prescribing information.

Patients can review general information about labeling and safety communications through the FDA drug safety section.

A label warning communicates safety information; it does not establish that the medication caused any individual patient’s tumor.

What Is a Meningioma?

A meningioma develops in the meninges, the protective tissue layers surrounding the brain and spinal cord.

Many meningiomas are noncancerous and grow slowly, but their location and size can still create serious medical problems by placing pressure on nearby structures.

The National Cancer Institute provides general information about brain and central nervous system tumors, including diagnosis and treatment.

Treatment depends on factors such as tumor size, location, growth, symptoms, and the patient’s overall health.

A medical team may recommend monitoring, surgery, radiation therapy, or another individualized approach.

Only qualified healthcare professionals can determine whether a patient’s symptoms warrant imaging or specialist evaluation.

Symptoms That Should Be Discussed With a Doctor

Meningioma symptoms vary because different areas of the brain and spinal cord control different functions.

Possible symptoms can include:

• Persistent or worsening headaches

• Changes in vision, including blurred or double vision

• Hearing loss or ringing in the ears

• Seizures

• Weakness or numbness in an arm or leg

• Problems with balance, memory, speech, or concentration

These symptoms can have many causes and do not necessarily indicate a tumor.

Anyone experiencing a new seizure, sudden neurological impairment, or another medical emergency should seek immediate care.

The National Institute of Neurological Disorders and Stroke offers additional information about neurological symptoms and conditions.

What Medical Research Has Reported

The label update follows growing research into possible associations between certain progestogens and meningioma.

A 2024 BMJ study reported an association between prolonged use of injectable medroxyprogesterone acetate and intracranial meningioma requiring surgery.

The study was observational, meaning it identified an association but could not by itself prove that the medication caused the tumors.

More recent research indexed by PubMed has continued to examine depot medroxyprogesterone acetate exposure, duration of use, and meningioma diagnoses.

Researchers must account for factors such as age, medical history, exposure duration, and differences between study populations.

For an individual patient, a diagnosis cannot be attributed to one medication solely because that medication appears in epidemiological research.

A treating physician may consider the patient’s complete medical and medication history when evaluating possible risk factors.

What Current and Former Patients Can Do

Patients should not make abrupt contraceptive decisions based only on a headline or lawsuit advertisement.

If you currently receive Depo-Provera, discuss the updated warning, your treatment history, and available contraceptive alternatives with your healthcare provider.

A productive appointment may include questions about:

• How long and how frequently you received injections

• Whether you have symptoms requiring neurological evaluation

• Whether a prior scan identified a meningioma or another abnormality

• The benefits and risks of continuing or changing contraception

• Whether referral to a neurologist, neurosurgeon, or other specialist is appropriate

People previously diagnosed with meningioma should ensure that every treating professional has an accurate medication history.

Do not delay urgent medical care while collecting records or investigating a possible legal claim.

What the Warning Means for Litigation

Plaintiffs have filed or pursued claims alleging that Depo-Provera exposure was associated with their meningiomas and that earlier warnings should have been provided.

The manufacturers may dispute causation, the adequacy of prior warnings, and whether a particular claim satisfies applicable legal requirements.

The FDA label update is not a court finding of fault, causation, or liability.

Likewise, the organization of lawsuits through multidistrict litigation is a case-management procedure rather than a decision that plaintiffs will prevail.

The Judicial Panel on Multidistrict Litigation explains how related federal civil cases may be coordinated for pretrial proceedings.

Each claim remains dependent on its own evidence, including exposure history, diagnosis, medical records, warning history, and filing deadlines.

Our Depo-Provera meningioma overview explains the allegations and information commonly reviewed during an initial case assessment.

Records That May Help Document Your History

Complete records can help physicians understand prior treatment and allow attorneys to evaluate the facts without relying on memory alone.

Relevant materials may include:

• Pharmacy, clinic, and gynecology records showing injection dates

• Insurance claims or billing records identifying the medication

• MRI, CT, pathology, surgical, and radiology reports

• Neurology, neurosurgery, ophthalmology, and emergency-care records

• Documentation of headaches, seizures, vision changes, or other symptoms

• Employment records reflecting medically related absences, when relevant

Patients can request records directly from providers even if a clinic has closed or changed ownership, although retrieval procedures and retention periods vary.

Keep original files intact and make copies for personal use.

A missing record does not automatically determine whether a claim can proceed, but early collection may prevent avoidable difficulties.

Filing Deadlines Require Individual Review

Drug-injury claims are subject to statutes of limitation and other timing rules that differ by jurisdiction and circumstance.

The relevant deadline may involve the date of diagnosis, discovery of a possible connection, medication use, or another event defined by applicable law.

A new warning does not automatically restart or extend every person’s filing period.

It is therefore risky to assume that ongoing litigation, medical treatment, or future settlement discussions preserve an unfiled claim.

An attorney evaluating a potential case will generally need the patient’s location history, treatment dates, diagnosis date, and information about when the possible association was discovered.

No article can determine the applicable deadline for a particular reader.

Take the Next Step

If you used Depo-Provera and were diagnosed with a meningioma, obtaining your injection and diagnostic records is a practical first step.

You can also request a confidential free case review so the specific medical history, alleged exposure, and possible filing deadlines can be evaluated.

A review does not guarantee that a lawsuit can be filed or predict any settlement, verdict, or other legal outcome.